<DOC>
	<DOCNO>NCT01707849</DOCNO>
	<brief_summary>Background : Hepatitis C recurrence , invariably occur viremic liver transplant ( LT ) recipient , associate accelerate liver fibrosis lead establish graft cirrhosis 40-20 % patient 5 year another 5 % experience aggressive form cirrhosis graft loss 1 year . Since treatment LT low efficacy , overall survival HCV-infected LT recipient shorter uninfected LT patient . New immunosuppressive agent mTOR inhibitor ( Everolimus/Sirolimus ) reduce risk liver graft rejection , antifibrotic property worsen HCV recurrence . Moreover new directly-acting antiviral agent increase efficacy interferon-based treatment use LT recipient may limited side effect . Hypothesis : Use individualize immunosuppressive regimen early personalize anti-viral treatment base recipient viral factor would improve outcome HCV infect liver transplant recipient . Objectives : 1 . To evaluate safety efficacy two steroid-free immunosuppressive regimen reduce hepatitis C recurrence associate fibrosis progression ( F≥2 ISHAK score ) one year post-transplant . 2 . To identify viral recipient factor associate liver fibrosis progression use ultra-deep pyrosequencing ( UDPS ) .</brief_summary>
	<brief_title>The Impact Everolimus Based Immunosuppression Evolution Hepatitis C Fibrosis After Liver Transplantation</brief_title>
	<detailed_description>Study design : A pilot , open-label , prospective , randomized unicenter study . As pilot study , number patient expect included n=40 . Inclusion criterion : - Age≥18 year - First liver transplant - RNA-HCV positive within 12 month previous transplant Exclusion criterion : - Multiorgan transplant - Split liver - ABO incompatible - HIV positive patient - Glomerular Filtration rate ≤60mL/min/1.73m2 Patients receive double immunosuppression therapy induction tacrolimus ( basal dose 0.1 mg/Kg/day ) mycophenolate mofetil ( MMF , basal dose 2g/day ) within first 12 hour skin closure . Patients randomize one follow group day 28th post-transplant : 1 . MMF group ( n=20 ) : tacrolimus ( level 8-10ng/ml ) MMF ( level 1-3ng/mL ) . 2 . EVL group ( n=20 ) : tacrolimus ( level 8-10ng/ml ) everolimus ( level 2- 4 ng/mL ) . HCV monitorization : - HVC-RNA detection quantification . Serum sample take immediately liver transplantation , anhepatic phase , begin end reperfusion , 1h , 4h , 8h , 12h , 18h , 1d , 3d , 7d , 14d , 28d , 2m , 3m , 6m , 9m 12m . Blood sample take peripheral circulation centrifugate within 2 3 hour extraction , aliquoted , frozen -80 ºC . The concentration HCV-RNA determine use quantitative reverse-transcription polymerase chain reaction ( RT-PCR ) assay ( Cobas Ampliprep/Cobas TaqMan ; Roche Molecular Diagnostics , Barcelona , Spain ) achieve sensitivity 15 UI/mL ultra deep pyrosequencing ( UDSP ) protocol use study DNA genomic factor viral RNA variability . - Serum fibrosis marker . Serum sample take 3rd , 6th 12th month post-transplant peripheral circulation frozen -21ºC . Serum marker ( HA , PIIINP , TIMP-1 ) analyze fully automate , two-site sandwich immunoassay use direct chemiluminometric technology ( ADVIA Centayr XP , Siemens Healthcare Diagnositics ) . The algorithm include three marker ( 3-M-ALG ) { score= -7,412 + [ ln ( HA ) x0,681 ] + [ ln ( PIIINP ) x0.775 ] + [ ln ( TIMP-1 ) ] x0,494 } also obtain . - Transient elastography ( FibroScan ) . Liver stiffness measurement use Fibroscan ( Echosens , Paris , France ) perform clinic 6th 12th month post-transplant . - Liver biopsy . Liver biopsy perform 12th month post-transplant . All biopsy specimens read single pathologist . Necroinflammatory activity fibrosis stage score use ISHAK classification . Follow-up clinical data : After discharge , patient visit outpatient clinic monthly first 3 month every 3 month thereafter first 12 month post-transplant , time clinical analytical variable recorded.Baseline characteristic , HCV genotype viral load transplant , surgical variable ( type liver transplant , donor age steatosis , ischemia time ) , post-transplantation information follow-up prospectively collect electronic database . Patient withdrawal : - No consent form give patient - Severe adverse event related immunosuppressor use - Steroids require long period time - Antiviral therapy give first year post-transplant - Lost follow-up - Patient death</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Age≥18 year First liver transplant RNAHCV positive within 12 month previous transplant Multiorgan transplant Split liver Fulminant hepatitis ABO incompatible HIV positive patient Glomerular Filtration rate ≤60mL/min/1.73m2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Liver Fibrosis</keyword>
	<keyword>m-TOR inhibitor</keyword>
</DOC>